197 related articles for article (PubMed ID: 34110696)
1. Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
Kobayashi M; Narita S; Matsui Y; Kanda S; Hidaka Y; Abe H; Tsuzuki T; Ito K; Kojima T; Kato M; Hatakeyama S; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Kamiyama M; Morita S; Habuchi T; Ogawa O; Nishiyama H; Kitamura H; Kobayashi T;
BJU Int; 2022 Aug; 130(2):226-234. PubMed ID: 34110696
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato A; Furubayashi N; Harada M; Negishi T; Sakamoto N; Song Y; Hori Y; Tomoda T; Tamura S; Kuroiwa K; Seki N; Tomisaki I; Harada K; Nakamura M; Fujimoto N
Clin Genitourin Cancer; 2022 Oct; 20(5):499.e1-499.e8. PubMed ID: 35624001
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology.
Minato A; Murooka K; Okumura Y; Takaba T; Higashijima K; Nagata Y; Tomisaki I; Harada K; Fujimoto N
In Vivo; 2024; 38(2):873-880. PubMed ID: 38418119
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.
Tsai TH; Su PJ; Huang SY; Kuo MC; Lin CT; Wu CC; Luo HL; Chen CH; Chou CC; Liu TT; Huang CC; Tsai KL; Su YL
BMC Cancer; 2023 Sep; 23(1):871. PubMed ID: 37715113
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
Krasnow RE; Drumm M; Roberts HJ; Niemierko A; Wu CL; Wu S; Zhang J; Heney NM; Wszolek MF; Blute ML; Feldman AS; Lee RJ; Zietman AL; Shipley WU; Efstathiou JA
Eur Urol; 2017 Jul; 72(1):54-60. PubMed ID: 28040351
[TBL] [Abstract][Full Text] [Related]
6. Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
Taoka R; Kobayashi T; Hidaka Y; Abe H; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Kamiyama M; Morita S; Ogawa O; Nishiyama H; Kitamura H; Sugimoto M;
Urol Oncol; 2022 Mar; 40(3):107.e1-107.e9. PubMed ID: 34454824
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Impact of Histopathological Variants in Patients with Advanced Urothelial Carcinoma.
Hsieh MC; Sung MT; Chiang PH; Huang CH; Tang Y; Su YL
PLoS One; 2015; 10(6):e0129268. PubMed ID: 26114748
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant Histology.
Arita Y; Yoshida S; Shigeta K; Kwee TC; Edo H; Okawara N; Hashimoto M; Ishii R; Ueda R; Mikami S; Fujiwara M; Waseda Y; Kikuchi E; Fujii Y; Jinzaki M
Eur Urol Oncol; 2023 Feb; 6(1):99-102. PubMed ID: 35933266
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.
Nishiyama N; Kobayashi T; Narita S; Hidaka Y; Ito K; Maruyama S; Mukai S; Tsutsumi M; Miki J; Okuno T; Yoshio Y; Matsumoto H; Shimazui T; Segawa T; Karashima T; Masui K; Fukuta F; Tashiro K; Imai K; Suekane S; Nagasawa S; Higashi S; Fukui T; Kojima T; Morita S; Ogawa O; Nishiyama H; Kitamura H;
J Geriatr Oncol; 2022 Jan; 13(1):88-93. PubMed ID: 34238726
[TBL] [Abstract][Full Text] [Related]
10. Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer.
Inoue S; Sassa N; Kawanishi H; Yuguchi Y; Suzuki T; Nagayama J; Matsui H; Miyata Y; Soeda Y; Tochigi K; Yamauchi Y; Maeda M; Kobayashi I; Hattori R; Matsukawa Y; Kato M
Anticancer Res; 2022 Jul; 42(7):3627-3636. PubMed ID: 35790259
[TBL] [Abstract][Full Text] [Related]
11. Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020).
Taguchi S; Kawai T; Nakagawa T; Miyakawa J; Kishitani K; Sugimoto K; Nakamura Y; Kamei J; Obinata D; Yamaguchi K; Kaneko T; Yoshida K; Yamamoto S; Kakutani S; Kanazawa K; Sugihara Y; Tokunaga M; Matsumoto A; Uemura Y; Akiyama Y; Yamada Y; Sato Y; Yamada D; Enomoto Y; Nishimatsu H; Ishikawa A; Tanaka Y; Nagase Y; Fujimura T; Fukuhara H; Takahashi S; Kume H
Int J Urol; 2022 Dec; 29(12):1462-1469. PubMed ID: 35996761
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Minato A; Furubayashi N; Nagata Y; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Harada K; Nakamura M; Fujimoto N
Curr Oncol; 2024 Feb; 31(2):862-871. PubMed ID: 38392058
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
14. Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.
Dang E; Vallée A; Lepage-Seydoux C; Sejean K; Bonan B; Abraham C; Beuzeboc P; Ratta R
Curr Oncol; 2022 Feb; 29(2):945-955. PubMed ID: 35200579
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G
Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857
[TBL] [Abstract][Full Text] [Related]
17. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
Jindal T; Zhang L; Deshmukh P; Reyes K; Chan E; Kumar V; Zhu X; Maldonado E; Feng S; Johnson M; Angelidakis A; Kwon D; Desai A; Borno HT; Bose R; Wong A; Hong J; Carroll P; Meng M; Porten S; Aggarwal R; Small EJ; Fong L; Chou J; Friedlander T; de Kouchkovsky I; Koshkin VS
Clin Genitourin Cancer; 2023 Oct; 21(5):e394-e404. PubMed ID: 37316414
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction.
Kita Y; Ito K; Kanda S; Joraku A; Yamaguchi R; Shimizu Y; Hayata N; Somiya S; Shibasaki N; Kimura T; Hikami K; Yamada T; Abe T; Tsuchihashi K; Tatarano S; Nishiyama H; Kitamura H; Kobayashi T
Urol Oncol; 2022 Sep; 40(9):410.e11-410.e18. PubMed ID: 35551861
[TBL] [Abstract][Full Text] [Related]
19. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
Taguchi S; Kawai T; Ambe Y; Kishitani K; Sugimoto K; Miyakawa J; Nakamura Y; Noda M; Kaneko T; Kamei J; Obinata D; Yamaguchi K; Kakutani S; Furuya Y; Sato Y; Uemura Y; Akiyama Y; Yamada Y; Sato Y; Yamada D; Enomoto Y; Nishimatsu H; Fujimura T; Fukuhara H; Nakagawa T; Takahashi S; Kume H
Int J Urol; 2023 Dec; 30(12):1180-1186. PubMed ID: 37740409
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
Mollica V; Tassinari E; Santoni M; Marchese PV; Giunchi F; Maloberti T; Tateo V; Ricci C; Rosellini M; Marchetti A; Fiorentino M; Biase D; Massari F
Pathol Res Pract; 2024 Jan; 253():155008. PubMed ID: 38103361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
